Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The PROTAC technology in drug development
Yutian Zou, Danhui Ma, Yinyin Wang
Cell Biochemistry and Function (2019) Vol. 37, Iss. 1, pp. 21-30
Open Access | Times Cited: 224

Showing 1-25 of 224 citing articles:

PROTACs: great opportunities for academia and industry
Xiuyun Sun, Hongying Gao, Yiqing Yang, et al.
Signal Transduction and Targeted Therapy (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 513
PROTACs: past, present and future
Ke Li, Craig M. Crews
Chemical Society Reviews (2022) Vol. 51, Iss. 12, pp. 5214-5236
Open Access | Times Cited: 419
Targeting RNA structures with small molecules
Jessica L. Childs‐Disney, Xueyi Yang, Quentin M. R. Gibaut, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 10, pp. 736-762
Open Access | Times Cited: 351
Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: Recent progress and future challenges
Scott D. Edmondson, Bin Yang, Charlene Fallan
Bioorganic & Medicinal Chemistry Letters (2019) Vol. 29, Iss. 13, pp. 1555-1564
Closed Access | Times Cited: 316
Artificial intelligence in drug discovery: recent advances and future perspectives
José Jiménez-Luna, Francesca Grisoni, Nils Weskamp, et al.
Expert Opinion on Drug Discovery (2021) Vol. 16, Iss. 9, pp. 949-959
Open Access | Times Cited: 302
Degradation of proteins by PROTACs and other strategies
Yang Wang, Xueyang Jiang, Feng Feng, et al.
Acta Pharmaceutica Sinica B (2019) Vol. 10, Iss. 2, pp. 207-238
Open Access | Times Cited: 254
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
Christiana M. Neophytou, Ioannis P. Trougakos, Nuray Erin, et al.
Cancers (2021) Vol. 13, Iss. 17, pp. 4363-4363
Open Access | Times Cited: 237
Molecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery
Guoqiang Dong, Yu Ding, Shipeng He, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 15, pp. 10606-10620
Closed Access | Times Cited: 223
PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
Simin Qi, Jinyun Dong, Zhiyuan Xu, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 205
Aptamer‐PROTAC Conjugates (APCs) for Tumor‐Specific Targeting in Breast Cancer
Shipeng He, Fei Gao, Junhui Ma, et al.
Angewandte Chemie International Edition (2021) Vol. 60, Iss. 43, pp. 23299-23305
Closed Access | Times Cited: 192
Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands
Xin Han, Lijie Zhao, Weiguo Xiang, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 24, pp. 11218-11231
Open Access | Times Cited: 191
Proteolysis‐targeting chimeras in drug development: A safety perspective
Kévin Moreau, Muireann Coen, Andrew X. Zhang, et al.
British Journal of Pharmacology (2020) Vol. 177, Iss. 8, pp. 1709-1718
Open Access | Times Cited: 161
Cyclin D-CDK4/6 functions in cancer
Xueliang Gao, Gustavo Leone, Haizhen Wang
Advances in cancer research (2020), pp. 147-169
Closed Access | Times Cited: 155
An overview of PROTACs: a promising drug discovery paradigm
Liu Zi, Mingxing Hu, Yang Yu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 153
Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader
Frances Potjewyd, Anne‐Marie W. Turner, Joshua Beri, et al.
Cell chemical biology (2019) Vol. 27, Iss. 1, pp. 47-56.e15
Open Access | Times Cited: 152
Liquid–liquid phase separation in tumor biology
Xuhui Tong, Rong Tang, Jin Xu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 135
From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation
Carlotta Cecchini, Sara Pannilunghi, Sébastien Tardy, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 123
Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer
Xin Han, Lijie Zhao, Weiguo Xiang, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 17, pp. 12831-12854
Open Access | Times Cited: 106
Structural Diversity of Ubiquitin E3 Ligase
Sachiko Toma-Fukai, Toshiyuki Shimizu
Molecules (2021) Vol. 26, Iss. 21, pp. 6682-6682
Open Access | Times Cited: 104
Emerging degrader technologies engaging lysosomal pathways
Yu Ding, Dong Xing, Yiyan Fei, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 21, pp. 8832-8876
Open Access | Times Cited: 76
Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy
Zhiqiang Wang, Zhao-Cong Zhang, Yuyang Wu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 67
Discovery of Nanomolar DCAF1 Small Molecule Ligands
Alice Shi Ming Li, Serah Kimani, Brian J. Wilson, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 7, pp. 5041-5060
Open Access | Times Cited: 44
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Chao Wang, Yujing Zhang, Wujun Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 29
Journey of PROTAC: From Bench to Clinical Trial and Beyond
Kyli Berkley, Julian Zalejski, Nidhi Sharma, et al.
Biochemistry (2025)
Closed Access | Times Cited: 3
Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway
Philipp Ottis, Chiara Palladino, Phillip Thienger, et al.
ACS Chemical Biology (2019)
Closed Access | Times Cited: 133
Page 1 - Next Page

Scroll to top